Jeffrey Locke

Dr. Jeffrey Locke


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DBDávid Balázsi
Dávid Balázsi
JMJacobus F. Meis
Jacobus F. Meis
JLJeffrey Locke
Jeffrey Locke
GUGergely Udvarhelyi
Gergely Udvarhelyi
TZTóth Zoltán
Tóth Zoltán
Laszlo MajorosLaszlo Majoros
Laszlo Majoros
Objectives: The aim of our study was to investigate the in vitro activity and in vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris isolates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs, according to CLSI M27-Ed4, and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutropenic mice were infected intravenously (1 × 107 CFU/mouse). Treatment was initiated 24 h post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06–0.25, ≤0.03–0.12, 0.12–0.5 and ≤0.03–0.12 mg/L, respectively. Growth in RPMI-1640 showed pseudohypha in all five isolates both at 30 °C and 37 °C, but hyphae were never observed. In contrast, echinocandin-treated yeasts at 37 °C showed small and large aggregates of blastoconidia at both 0.25 and 16 mg/L echinocandin concentrations. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens improved the survival in mice infected with isolates MRL40 and IFRC4050 (p-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TMML617 (p = 0.0049). All four echinocandins induced more than 4 log mean CFU/gram decreases in the kidneys and hearts of mice infected with isolate MRL40 (p < 0.001 for all echinocandins). Rezafungin and caspofungin significantly decreased the fungal kidney and heart burdens in mice infected with isolate TMML617. Against IFRC4050, rezafungin, anidulafungin and caspofungin significantly decreased the fungal burdens in the kidneys (p < 0.05) and hearts (p < 0.05–0.01). The fungal brain tissue burdens were always higher than 105 CFU/gram. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin-treated mice, only blastoconidia were observed. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphae production was common in controls, but not in echinocandin-treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.

8 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DBDávid Balázsi
Dávid Balázsi
JMJacobus F. Meis
Jacobus F. Meis
JLJeffrey Locke
Jeffrey Locke
GUGergely Udvarhelyi
Gergely Udvarhelyi
TZTóth Zoltán
Tóth Zoltán
Laszlo MajorosLaszlo Majoros
Laszlo Majoros
Objectives: The aim of our study was to investigate the in vitro activity and in vivo effica-cy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris iso-lates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutro-penic mice were infected intravenously (107 CFU/mouse). Treatment was initiated 24 hours post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06-0.25, ≤0.03-0.12, 0.12-0.5 and ≤0.03-0.12 mg/L, respectively. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens im-proved the survival in mice infected with isolates MRL40 and IFRC4050 (P-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TML617 (P=0.0049). All four echinocandins induced more than 3 logs mean CFU/gram decreases in the kidneys and hearts of mice infected with the three isolates compared to control mice, some of which were not statistically significant. Fungal growth, regardless of the isolate tested, was poorly inhibited by echinocandins in the brain. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin treated mice only blastoconidia were found. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphal production was common in controls, but not in echinocandin treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.